Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment.
作者信息
Wright Jean L, Rahbar Habib, Obeng-Gyasi Samilia, Carlos Ruth, Tjoe Judy, Wolff Antonio C
机构信息
Johns Hopkins University, Baltimore, MD.
University of Washington, Seattle, WA.
出版信息
J Clin Oncol. 2022 Jan 20;40(3):225-230. doi: 10.1200/JCO.21.01674. Epub 2021 Nov 23.
Abstract
摘要
相似文献
1
Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment.克服导管原位癌治疗中的障碍：从过度治疗到优化治疗。
J Clin Oncol. 2022 Jan 20;40(3):225-230. doi: 10.1200/JCO.21.01674. Epub 2021 Nov 23.
2
A Call for Change in the Diagnosis and Treatment of Patients with Ductal Carcinoma In Situ: An Opportunity to Minimize Overdiagnosis and Overtreatment.呼吁改变导管原位癌患者的诊断与治疗：减少过度诊断和过度治疗的契机
Breast J. 2015 Nov-Dec;21(6):575-8. doi: 10.1111/tbj.12526.
3
Re: Trends in the treatment of ductal carcinoma in situ of the breast.关于：乳腺导管原位癌的治疗趋势。
J Natl Cancer Inst. 2004 Aug 18;96(16):1257; author reply 1259-60. doi: 10.1093/jnci/djh248.
4
Avoiding Overtreatment of Ductal Carcinoma in situ.避免导管原位癌的过度治疗。
Trends Cancer. 2019 Jul;5(7):391-393. doi: 10.1016/j.trecan.2019.05.005. Epub 2019 Jun 20.
5
Renaming ductal carcinoma in situ: would removing "carcinoma" reduce overtreatment?导管原位癌更名：去除“癌”字会减少过度治疗吗？
J Natl Compr Canc Netw. 2014 Apr;12(4):599-602. doi: 10.6004/jnccn.2014.0060.
6
Controversies in Screening Mammography.乳腺钼靶筛查的争议
Clin Obstet Gynecol. 2016 Jun;59(2):351-61. doi: 10.1097/GRF.0000000000000205.
7
[Ductal carcinoma in situ].导管原位癌
Ugeskr Laeger. 2018 Sep 17;180(38).
8
Diagnosis of ductal carcinoma in situ in an era of de-escalation of therapy.在治疗降级的时代诊断导管原位癌。
Mod Pathol. 2021 Jan;34(Suppl 1):1-7. doi: 10.1038/s41379-020-00665-x. Epub 2020 Sep 9.
9
Current Trends in the Management of Ductal Carcinoma In Situ.导管原位癌管理的当前趋势
Oncology (Williston Park). 2016 Sep 15;30(9):823-31.
10
Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer.乳腺癌的过度诊断与过度治疗：两项乳腺癌钼靶筛查试验中的过度诊断估计
Breast Cancer Res. 2005;7(6):258-65. doi: 10.1186/bcr1354. Epub 2005 Nov 10.
引用本文的文献
1
Cooperative CCL2/CCR2 and HGF/MET signaling enhances breast cancer growth and invasion associated with metabolic reprogramming.协同的CCL2/CCR2和HGF/MET信号传导增强与代谢重编程相关的乳腺癌生长和侵袭。
Cancer Biol Ther. 2025 Dec;26(1):2535824. doi: 10.1080/15384047.2025.2535824. Epub 2025 Jul 30.
2
Mammography screening and incidence of ductal carcinoma in situ of the breast in Italy: an age-period-cohort analysis.意大利乳腺钼靶筛查与乳腺导管原位癌发病率：年龄-时期-队列分析
Int J Epidemiol. 2025 Jun 11;54(4). doi: 10.1093/ije/dyaf102.
3
Multiplex characterization of circulating tumor cells from ductal carcinoma in situ patients suggests early tumor dissemination.导管原位癌患者循环肿瘤细胞的多重表征提示肿瘤早期播散。
Cancer Lett. 2025 Jul 28;623:217703. doi: 10.1016/j.canlet.2025.217703. Epub 2025 Apr 16.
4
The Genomic and Biologic Landscapes of Breast Cancer and Racial Differences.乳腺癌的基因组和生物学特征及种族差异
Int J Mol Sci. 2024 Dec 7;25(23):13165. doi: 10.3390/ijms252313165.
5
Multimodal genome-wide survey of progressing and non-progressing breast ductal carcinoma in-situ.进展期与非进展期乳腺导管原位癌的多模态全基因组调查。
Breast Cancer Res. 2024 Dec 4;26(1):178. doi: 10.1186/s13058-024-01927-1.
6
Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast.癌症易感基因中的致病变异易导致乳腺导管原位癌。
Clin Cancer Res. 2025 Jan 6;31(1):130-138. doi: 10.1158/1078-0432.CCR-24-1884.
7
Exploring non-surgical alternatives for low to intermediate-grade ductal carcinoma of the breast using vacuum-assisted excision: the VACIS protocol.使用真空辅助切除术探索低至中等级别乳腺导管癌的非手术替代方案：VACIS方案。
Front Med (Lausanne). 2024 Sep 24;11:1467738. doi: 10.3389/fmed.2024.1467738. eCollection 2024.
8
Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study.保乳手术联合放疗治疗乳腺导管原位癌：ECOG-ACRIN E5194研究的20年结果 。
你提供的原文可能存在信息错误，根据标题推测正确的英文原文应该是“Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study.”，对应的中文译文为“乳腺导管原位癌保乳手术不联合放疗：ECOG-ACRIN E5194研究的20年结果” 。 你可以检查下原文信息，以便我为你提供更准确的翻译。 上述译文是纠正错误后按照要求为你提供的内容。
NPJ Breast Cancer. 2024 Feb 24;10(1):16. doi: 10.1038/s41523-024-00622-w.
9
Perioperative care of nipple-areola complex-sparing mastectomy and one-stage breast reconstruction via endoscopic axillary approach for ductal carcinoma in situ: A case report.腔镜腋窝入路保乳头乳晕复合体的乳腺癌改良根治术同期乳房再造术的围手术期护理：一例报告。
Medicine (Baltimore). 2023 Dec 15;102(50):e36173. doi: 10.1097/MD.0000000000036173.
10
The Feasibility of Omitting Postoperative Radiotherapy in Japanese Patients With Ductal Carcinoma In Situ of Breast Treated With Breast-Conserving Surgery.对接受保乳手术治疗的日本乳腺导管原位癌患者省略术后放疗的可行性
Cureus. 2023 Nov 2;15(11):e48187. doi: 10.7759/cureus.48187. eCollection 2023 Nov.
本文引用的文献
1
The Effect of a 6-Month Exercise Intervention Trial on Allostatic Load in Black Women at Increased Risk for Breast Cancer: the FIERCE Study.一项为期 6 个月的运动干预试验对有乳腺癌风险增加的黑人女性的身体压力负荷的影响：FIERCE 研究。
J Racial Ethn Health Disparities. 2022 Oct;9(5):2063-2069. doi: 10.1007/s40615-021-01145-x. Epub 2021 Sep 27.
2
Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.随机 III 期临床试验评估手术切除后低危导管原位癌的放疗：NRG 肿瘤学/RTOG9804 的长期报告。
J Clin Oncol. 2021 Nov 10;39(32):3574-3582. doi: 10.1200/JCO.21.01083. Epub 2021 Aug 18.
3
Preoperative breast magnetic resonance imaging in patients with ductal carcinoma in situ: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC).术前乳腺磁共振成像在导管原位癌患者中的应用： 欧洲委员会乳腺癌倡议（ECIBC）的系统评价。
Eur Radiol. 2021 Aug;31(8):5880-5893. doi: 10.1007/s00330-021-07873-2. Epub 2021 May 30.
4
Breast MRI in the setting of DCIS: quality trials are still needed to determine its value.导管原位癌情况下的乳腺磁共振成像：仍需进行高质量试验以确定其价值。
Eur Radiol. 2021 Aug;31(8):5877-5879. doi: 10.1007/s00330-021-08057-8. Epub 2021 May 28.
5
Breast MRI in DCIS size estimation, breast-conserving surgery and oncoplastic breast surgery.乳腺磁共振成像在导管原位癌大小评估、保乳手术及肿瘤整形乳房手术中的应用
Cancer Treat Rev. 2021 Mar;94:102158. doi: 10.1016/j.ctrv.2021.102158. Epub 2021 Feb 2.
6
Deconstructing Racial and Ethnic Disparities in Breast Cancer.剖析乳腺癌中的种族和族裔差异
JAMA Oncol. 2021 Mar 1;7(3):355-356. doi: 10.1001/jamaoncol.2020.7113.
7
Use of the Twelve-Gene Recurrence Score for Ductal Carcinoma in Situ and Its Influence on Receipt of Adjuvant Radiation and Hormonal Therapy.十二基因复发评分在导管原位癌中的应用及其对辅助放疗和激素治疗的影响。
Ann Surg Oncol. 2021 Aug;28(8):4294-4303. doi: 10.1245/s10434-020-09517-z. Epub 2021 Jan 18.
8
Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection.美国癌症和 COVID-19 感染患者的风险、种族差异和结局分析。
JAMA Oncol. 2021 Feb 1;7(2):220-227. doi: 10.1001/jamaoncol.2020.6178.
9
Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study.乳腺癌与 MRI 背景实质增强的相关性：IMAGINE 病例对照研究。
Breast Cancer Res. 2020 Dec 7;22(1):138. doi: 10.1186/s13058-020-01375-7.
10
The wisdom trial is based on faulty reasoning and has major design and execution problems.智慧试验的推理是错误的，存在重大设计和执行问题。
Breast Cancer Res Treat. 2021 Feb;185(3):549-556. doi: 10.1007/s10549-020-06020-7. Epub 2020 Nov 25.
Zotero 插件